Bayforest Capital’s Recursion Pharmaceuticals RXRX Stock Holding History

Bayforest Capital’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7	Closed	-$34	–	933
2025 Q3	$34	Buy	+7	New	+$37	﹤0.01%	714
2025 Q1	–	Sell	-31,781	Closed	-$215K	–	874
2024 Q4	$215K	Buy	+31,781	New	+$214K	0.27%	123

Other funds holding RXRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Bayforest Capital's RXRX Position: Q4 2025 in Review

Bayforest Capital sold out of Recursion Pharmaceuticals (RXRX) in Q4 2025, closing a stake of 7 shares — an estimated $34 sold.

Bayforest Capital first reported a position in RXRX in Q4 2024 and held it in 2 quarters. The position peaked at $215K in Q4 2024. 333 funds tracked by Wall St. Rank hold RXRX as of Q4 2025.

Bayforest Capital reported no remaining Recursion Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Bayforest Capital sold 7 Recursion Pharmaceuticals shares in Q4 2025, an estimated $34.
Bayforest Capital first reported a position in Recursion Pharmaceuticals in Q4 2024 and held it in 2 quarters.
Bayforest Capital's Recursion Pharmaceuticals position peaked at $215K in Q4 2024.
333 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2025.

Based on Bayforest Capital's 13F filing for Q4 2025, filed 27 Jan 2026.